T. Rowe Price Investment Management, Inc. 13D and 13G filings for Black Diamond Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 1:28 pm Purchase |
2024-09-30 | 13G | Black Diamond Therapeutics, Inc. BDTX |
T. Rowe Price Investment Management, Inc. | 10,734,389 19.000% |
74,659 (+0.70%) |
Filing |
| 2024-07-10 2:17 pm Purchase |
2024-06-30 | 13G | Black Diamond Therapeutics, Inc. BDTX |
T. Rowe Price Investment Management, Inc. | 10,659,730 18.900% |
3,983,974 (+59.68%) |
Filing |
| 2024-03-11 1:14 pm Purchase |
2024-02-29 | 13G | Black Diamond Therapeutics, Inc. BDTX |
T. Rowe Price Investment Management, Inc. | 6,675,756 12.900% |
2,747,877 (+69.96%) |
Filing |
| 2024-02-14 10:04 am Purchase |
2023-12-31 | 13G | Black Diamond Therapeutics, Inc. BDTX |
T. Rowe Price Investment Management, Inc. | 3,927,879 7.600% |
3,927,879 (New Position) |
Filing |